Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LUPIN.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LUPIN.BO and 80,000+ other tickers.
See exactly how LUPIN.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LUPIN.BO and 80,000+ other tickers.
Lupin Limited functions as a global pharmaceutical enterprise, dedicated to the research, development, production, marketing, and distribution of a broad spectrum of products. These include both proprietary and generic drug formulations, biotechnology products, and active pharmaceutical ingredients (APIs), catering to markets within India and internationally. The company's therapeutic offerings span numerous medical fields, such as cardiovascular diseases, diabetology, asthma, pediatrics, central nervous system conditions, gastrointestinal disorders, anti-infectives, nonsteroidal…
No recent news available.